@article{TCR1379,
author = {Kim Phan and Kathryn Martires and Dave E. Kurlander and Kishore Gaddipati and Marin Xavier},
title = {The incidence of second primary malignancies after gastrointestinal stromal tumor before and after the introduction of imatinib mesylate},
journal = {Translational Cancer Research},
volume = {3},
number = {2},
year = {2013},
keywords = {},
abstract = {Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. Imatinib mesylate was FDA-approved in 2002 for the treatment of unresectable and metastatic GISTs and has become the standard of care. Its use has resulted in greatly increased survival rates for patients with GIST. The increased survival in patients with GIST raises concerns about long term effects of therapy, particularly the development of second primary malignancies (SPMs), which has been reported with imatinib treatment of chronic myeloid leukemia. In addition, the diagnosis of GIST itself may pose a risk for the development of SPMs. The purpose of this study was to examine the incidence of SPMs after GIST, particularly before (pre-imatinib era: 1992-2001) and after (imatinib era: 2002-2009), and factors related to the occurrence of SPMs. Data from the NCI’s Surveillance Epidemiology and End Results (SEER) 1992-2009 program was utilized. Standardized incidence ratios (SIRs) and 95% confidence intervals (CIs) for these were calculated using SEER*Stat 8.0.1. Observed incidences were then compared between pre-imatinib and imatinib eras using Fisher’s exact test. The relationship between the presence of SPMs and each of the variables was examined using logistic regression. There were significantly more patients in the imatinib era alive after follow-up (n=533, 63.99%) than in the pre-imatinib era (n=130, 22.41%, P},
issn = {2219-6803}, url = {https://tcr.amegroups.org/article/view/1379}
}